Despite the uncertainties of Fiscal Cliff, dividend stocks have emerged as a rock solid investment. Given how tough it is to get income from other alternatives, dividend stocks are likely to remain an essential part of the portfolio of those income hungry investors who live off their investments. With alternative income producing options offering low interest rates and banks offering meager returns on saving accounts, investors have had a little choice other than scouring for dividend paying stocks. In continuation to my last post, I explored the investing landscape a bit more to identify three more dividend stocks which can be a great addition to any investor’s portfolio. Let’s discuss each of these stocks in detail.
|Companies||5 year average yield||Forward annual yield||Payout Ratio|
|GlaxoSmithKline plc (NYSE:GSK)||4.80%||5.10%||78.0%|
|Gannett Co., Inc. (NYSE:GCI)||5.70%||4.30%||37.0%|
|The Coca-Cola Company (NYSE:KO)||2.80%||2.70%||52.0%|
Source: Yahoo Finance
The company’s stock price has again gained momentum after hitting a low of ~$41 in November post its third quarter results. The overall performance of the company was impacted by a weak market in Europe. In 2012, the company witnessed price cuts in Europe that squeezed its gross margins. However, I expect this burden to have less effect in the fourth quarter results as the company has now stabilized its operations in Europe by cutting its costs. It included major headcount reductions in EU management, divesting its EU headquarters operations, and combining the EU and emerging markets management teams. Moreover, Glaxo has concentrated its focus on Europe in its R&D mix and is emphasizing more on Japan, China, and Brazil. These corrective measures should help Glaxo in posting steady returns in 2013.
Another positive for Glaxo is its well-placed position in therapeutic cancer vaccines. The company is running trials for MAGE-A3 for metastatic melanoma and non-small cell lung cancer. Looking at the company’s strong record of very less number of errors in clinical trials, I feel this is a good chance for Glaxo to make a breakthrough. The phase II trials have already shown good results and the same statistical significance is expected from phase III results, to be released by mid of 2013. I expect ~10% upside to the company’s value on the release of positive data. The company could be a strong beneficiary in this area, as this a high risk-reward opportunity.
Gannett is a consistent dividend payer in Buffett’s portfolio with an average of ~5.7% dividend yield in the last five years. Also the shareholders have all the reasons to celebrate with the company’s stock price mounting upwards with a solid return of ~40% in the last six months. It is currently trading at ~$20, which is its highest level in the last two years. Gannett has been successful in adapting to the changing needs of media by adding new revenue generating channels. A further upside is expected in its stock price considering its subscription revenue growth in 2013. Additionally, the company’s content subscription model has been launched in 78 markets and is expecting the revenue to increase by ~25%. This in turn would generate ~$100 million of operating profit in 2013. I further expect the Gannett’s digital subscribers to grow by 5-7x in 2013.
Apart from this, the company’s cash flow is at ~14% of its sales which is highest among its peers. And, I expect it to generate ~700 million of FCF in 2013. The funds could be used in buying out assets of CareerBuilder which the Tribune Co has announced after coming out of bankruptcy. Gannett already has ~53% stake in this company and it would be the first choice for further investment. I feel this move would help the company to add another stream of revenue along with reducing its dependence on newspapers.